Table 4 The demographic and clinical characteristics of patients with stage 4 lung cancer at baseline PET/CT
Variable | STM (n = 74) | Non-STM (n = 73) | Total (n = 147) |
|---|---|---|---|
\( \boldsymbol{N}\overline{/\boldsymbol{x}}\pm \boldsymbol{s} \) | \( \boldsymbol{N}\overline{/\boldsymbol{x}}\pm \boldsymbol{s} \) | \( \boldsymbol{N}\overline{/\boldsymbol{x}}\pm \boldsymbol{s} \) | |
Age (years) | 61.2 ± 11.8 | 62.8 ± 11.1 | 62.0 ± 11.5 |
Sex | |||
 Female | 24 | 25 | 49 |
 Male | 50 | 48 | 98 |
Histology of lung cancer | |||
 ADC | 44 | 44 | 88 |
 SCLC | 10 | 11 | 21 |
 LCC | 1 | 3 | 4 |
 SqCC | 11 | 12 | 23 |
 ASCC | 2 | 0 | 2 |
NSCLC-NOS | 6 | 3 | 9 |
SUVmax of lung cancer | 10.9 ± 5.7 | 12.2 ± 7.1 | 11.5 ± 6.4 |
Bone metastasis | |||
 No | 32 | 17 | 49 |
 Yes | 42 | 56 | 98 |
Hepatic metastasis | |||
 No | 59 | 54 | 113 |
 Yes | 15 | 19 | 34 |
Brain metastasis | |||
 No | 63 | 62 | 125 |
 Yes | 11 | 11 | 22 |
Adrenal gland metastasis | |||
 No | 58 | 51 | 109 |
 Yes | 16 | 22 | 38 |
Metastasis within chest cavity | |||
 No | 56 | 52 | 108 |
 Yes | 18 | 21 | 39 |
Other distant metastasis | |||
 No | 71 | 69 | 140 |
 Yes | 3 | 4 | 7 |
SUVmax of STM | 5.8 ±4.0 | / | / |
First manifestation | |||
 Primary tumor or other | 65 | / | / |
 metastasis |  |  |  |
 STM | 9 | / | / |
Accompanied by other metastasis | |||
 Yes | 69 | / | / |
 No | 5 | / | / |
Survival situation | |||
 Death | 65 | 67 | 132 |
 Survival | 9 | 6 | 15 |
Median survival time (months) | 5.0 ± 12.7 | 6.0 ± 12.3 | 5.5 ± 12.4 |